Trastuzumab, a recombinant humanized IgG1 antibody against the extracellular domain of HER2, blocks the HER2 receptor on the cell surface, sensitizes cancer cells to the tumor necrosis factor (TNF) and inhibits neoangiogenesis. This evidence concerns the gene ERBB2 and cancer.